LONG-TERM EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TUMOR NECROSIS FACTOR THERAPY: RESULTS OF THE RANDOMIZED, PHASE 3 SIRROUND-T STUDY

被引：0
|
作者：
Tanaka, Y. [1 ]
Aletaha, D. [2 ]
Agarwal, P. [3 ]
Kurrasch, R. [4 ]
Tak, P. P. [5 ]
Popik, S. [3 ]
机构：
[1] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan
[2] Med Univ Vienna, Div Rheumatol, Vienna, Austria
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Stevenage, Herts, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.6486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0214
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of sirukumab in patients with active rheumatoid arthritis despite disease-modifying anti-rheumatic drug treatment: results of a randomized, double-blind, placebo-controlled study
    Takeuchi, T.
    Thorne, C.
    Karpouzas, G.
    Sheng, S.
    Xu, W.
    Rao, R.
    Fei, K.
    Hsu, B.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 22 - 23
  • [32] Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study
    Westhovens, Rene
    Winthrop, Kevin L.
    Kavanaugh, Arthur
    Greenwald, Maria
    Dagna, Lorenzo
    Cseuz, Regina
    Besuyen, Robin
    de Vries, Dick
    Modgill, Vikas
    Le, Ly Huong
    Genovese, Mark C.
    Emery, Paul
    Verschueren, Patrick
    Alten, Rieke
    RMD OPEN, 2025, 11 (01):
  • [33] Safety and Efficacy of Anti-Tumor Necrosis Factor α Therapy in Ten Patients With Recent-Onset Refractory Reactive Arthritis
    Meyer, Alain
    Chatelus, Emmanuel
    Wendling, Daniel
    Berthelot, Jean-Marie
    Dernis, Emmanuelle
    Houvenagel, Eric
    Morel, Jacques
    Richer, Olivier
    Schaeverbeke, Thierry
    Gottenberg, Jacques-Eric
    Sibilia, Jean
    ARTHRITIS AND RHEUMATISM, 2011, 63 (05): : 1274 - 1280
  • [34] Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study
    Esposito, Maria
    Giunta, Alessandro
    Mazzotta, Annamaria
    Zangrilli, Arianna
    Babino, Graziella
    Bavetta, Mauro
    Perricone, Roberto
    Chimenti, Sergio
    Chimenti, Maria Sole
    DERMATOLOGY, 2012, 225 (04) : 312 - 319
  • [35] Long-term survival of subcutaneous anti-tumor necrosis factor biological drugs administered between 2008 and 2012 in a cohort of rheumatoid arthritis patients
    Alvarez Rivas, Noelia
    Vazquez Rodriguez, Tomas R.
    Miranda Filloy, Jose A.
    Garcia-Porrua, Carlos
    Sanchez-Andrade Fernandez, Amalia
    REUMATOLOGIA CLINICA, 2019, 15 (01): : 54 - 57
  • [36] Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy
    Li, Zhanguo
    Zhang, Fengchun
    Kay, Jonathan
    Fei, Kaiyin
    Han, Chenglong
    Zhuang, Yanli
    Wu, Zhong
    Hsia, Elizabeth C.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (11) : 1143 - 1156
  • [37] Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
    Li, Zhanguo
    Zhang, Fengchun
    Kay, Jonathan
    Fei, Kaiyin
    Han, Chenglong
    Zhuang, Yanli
    Wu, Zhong
    Hsia, Elizabeth C.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S598 - S599
  • [38] SAFETY AND EFFICACY OF SUBCUTANEOUS GOLIMUMAB IN CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE MTX THERAPY: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3 TRIAL
    Li, Z.
    Zhang, F.
    Kay, J.
    Fei, K.
    Han, C.
    Zhuang, Y.
    Wu, Z.
    Hsia, E. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 444 - 444
  • [39] THE EFFECT OF LONG-TERM THERAPY OF TUMOR NECROSIS FACTOR INHIBITORS ON MINERAL BONE DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Jankovic, T.
    Zvekic-Svorcan, J.
    Mikov, A.
    Krasnik, R.
    Vuklis, D.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S145 - S145
  • [40] Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry
    Harrold, Leslie R.
    Reed, George W.
    Magner, Robert
    Shewade, Ashwini
    John, Ani
    Greenberg, Jeffrey D.
    Kremer, Joel M.
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
12345